EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real‐world observations of GLP‐1 receptor agonists and SGLT‐2 inhibitors as potential treatments for Alzheimer's disease

Pengyue Zhang iD, Chengsheng Mao, Anna Sun, Yuedi Yang, Yuan Hou, Zhimin Fu, Tousi Babak, James B Leverenz, Andrew A Pieper, Yuan Luo, Jeffrey Cummings, Feixiong Cheng

Alzheimer's & Dementia · 2025-09 · 21 (9)

DOI: 10.1002/alz.70639 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 02.09.2025. Verfasst von Pengyue Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, Case Western Reserve University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Glucagon‐like peptide‐1 (GLP‐1) receptor agonists, sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors, and dipeptidyl peptidase‐4 (DPP‐4) inhibitors have potential beneficial effects in Alzheimer's disease (AD). METHODS We conducted pharmacoepidemiologic studies using two large‐scale real‐world databases. We fitted covariate‐adjusted Cox models to compare the risks of AD among initiators of GLP‐1 receptor agonists, SGLT‐2 inhibitors, and DPP‐4 inhibitors. RESULTS We identified GLP‐1 receptor agonist initiation compared to DPP‐4 inhibitors initiation was associated with a reduced risk of AD (hazard ratio [HR] ≤ 0.69 and P value < 0.001) and SGLT‐2 inhibitor initiation compared to DPP‐4 inhibitor initiation was associated with a reduced risk of AD (HR ≤ 0.67 and P value < 0.001). DISCUSSION GLP‐1 receptor agonist initiation and SGLT‐2 inhibitor initiation are associated with a reduced risk of AD. Randomized clinical trials are warranted to validate the causal beneficial effects of GLP‐1 receptor agonists and SGLT‐2 inhibitors in AD. Highlights Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are significantly associated with a reduced risk of Alzheimer's disease (AD) compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitors. Sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors are significantly associated with a reduced risk of AD compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitors. Two GLP‐1 receptor agonists (liraglutide and semaglutide) and three SGLT‐2 inhibitors (dapagliflozin, canagliflozin, and empagliflozin) are associated with a reduced risk of AD in drug‐specific sensitivity analyses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsHumansMaleAgedFemalePharmacoepidemiologyAged, 80 and over

Stichwörter der Autor:innen

Alzheimer's diseaseParkinson's diseasedipeptidyl peptidase‐4glucagon‐like peptide‐1real‐world datasodium‐glucose cotransporter‐2

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsDipeptidyl-Peptidase IV InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, Indiana, USA.
  • Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Cleveland Clinic Genome Center, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • College of Pharmacy, Northeast Ohio Medical University, Rootstown, Ohio, USA.
  • Department of Medicine, Cleveland Clinic Akron General, Cleveland Clinic, Akron, Ohio, USA.

ORCID-Profile: Pengyue Zhang

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS
  • Case Western Reserve University
  • Cleveland Alzheimer's Disease Research Center
  • NLM NIH HHS
  • University Hospitals Morley-Mather Chair in Neuropsychiatry
  • Valour Foundation
  • Alzheimer's Disease Drug Discovery Foundation (ADDF)

Zitieren

APA

Zhang, P., Mao, C., Sun, A., Yang, Y., Hou, Y., Fu, Z., Babak, T., Leverenz, J. B., Pieper, A. A., Luo, Y., Cummings, J., & Cheng, F. (2025). Real‐world observations of GLP‐1 receptor agonists and SGLT‐2 inhibitors as potential treatments for Alzheimer's disease. Alzheimer's & Dementia, 21(9). https://doi.org/10.1002/alz.70639

Vancouver

Zhang P, Mao C, Sun A, Yang Y, Hou Y, Fu Z, et al. Real‐world observations of GLP‐1 receptor agonists and SGLT‐2 inhibitors as potential treatments for Alzheimer's disease. Alzheimer's & Dementia. 2025;21(9). doi:10.1002/alz.70639

BibTeX
@article{Zhang2025,
  author = {Zhang, Pengyue and Mao, Chengsheng and Sun, Anna and Yang, Yuedi and Hou, Yuan and Fu, Zhimin and Babak, Tousi and Leverenz, James B and Pieper, Andrew A and Luo, Yuan and Cummings, Jeffrey and Cheng, Feixiong},
  title = {Real‐world observations of GLP‐1 receptor agonists and SGLT‐2 inhibitors as potential treatments for Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {9},
  doi = {10.1002/alz.70639}
}
Kostenlos starten →